Filing Flows › Utah Medical Products (UTMD) › Q1 2026 › vs Q1 2025
Utah Medical Products (UTMD) Q1 2026 vs Q1 2025 (year over year)
Utah Medical Products's revenue fell $988K (-10%) from $9.7M in Q1 2025 to $8.7M in Q1 2026. Gross margin 60.6% against 57.0% (+3.5 pts).
Utah Medical Products, Q1 2026: revenue $8.7M (-10% year over year), operating margin 29.4%, net earnings $2.6M, operating cash flow $3.1M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 60.6% | 57.0% | +3.5 pts |
| Operating margin | 29.4% | 32.5% | -3.1 pts |
| Net margin | 29.9% | 31.3% | -1.5 pts |
| Free cash flow margin | 34.2% | 44.1% | -9.9 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.7M | $9.7M | −$988K | -10% |
| Gross profit | $5.3M | $5.5M | −$256K | -5% |
| Cost of revenue | $3.4M | $4.2M | −$732K | -18% |
| Other income, net | $617K | $705K | −$88K | -12% |
| Operating profit | $2.6M | $3.2M | −$588K | -19% |
| Operating expenses | $2.7M | $2.4M | $332K | +14% |
| Pre-tax earnings | $3.2M | $3.9M | −$676K | -18% |
| Research & development | $154K | $154K | $0 | 0% |
| SG&A | $2.6M | $2.2M | $332K | +15% |
| Net earnings | $2.6M | $3.0M | −$437K | -14% |
| Income tax | $578K | $817K | −$239K | -29% |
| Depreciation & amortization | $673K | $709K | −$36K | -5% |
| Share-based compensation | $120K | $82K | $38K | +46% |
| Working capital & other | $288K | −$632K | $920K | — |
| Operating cash flow | $3.1M | $4.5M | −$1.4M | -30% |
| Free cash flow (OCF − capex) | $3.0M | $4.3M | −$1.3M | -30% |
| Capital expenditures | $130K | $184K | −$54K | -29% |
Questions
How much did Utah Medical Products's revenue grow year over year in Q1 2026?
Utah Medical Products's revenue fell $988K (-10%) from $9.7M in Q1 2025 to $8.7M in Q1 2026. Gross margin 60.6% against 57.0% (+3.5 pts).